Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06129864 · ClinicalTrials.gov registry record · Phase 3

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

A Phase 3 study of Locally Advanced Head and Neck Squamous Cell Carcinoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
1,145
Enrollment target
20
Study locations

NCT06129864 is a Phase 3 study of Locally Advanced Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,145 participants, above the 119-participant average among 5 other Locally Advanced Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (862% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06129864, a Phase 3 study of Locally Advanced Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
1,145 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).

Conditions Studied

Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG volrustomig

Study Locations (20)

California

  • Research Site - Fountain Valley
  • Research Site - Los Angeles
  • Research Site - Orange
  • Research Site - San Francisco
  • Research Site - Santa Rosa
  • Research Site - Whittier

Florida

  • Research Site - Fort Myers
  • Research Site - Gainesville
  • Research Site - Miami
  • Research Site - Palm Bay
  • Research Site - West Palm Beach

Colorado

  • Research Site - Aurora
  • Research Site - Colorado Springs
  • Research Site - Lone Tree

Arizona

  • Research Site - Phoenix
  • Research Site - Prescott Valley

Alabama

  • Research Site - Birmingham

Arkansas

  • Research Site - Springdale

District of Columbia

  • Research Site - Washington D.C.

Illinois

  • Research Site - Niles

Trial Details

FieldValue
Enrollment Target 1,145 participants
Start Date 2023-12-14
Est. Completion 2030-09-12
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06129864

The ClinicalTrials.gov registry entry for NCT06129864 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,145 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 119-participant average among 5 other Locally Advanced Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (862% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Locally Advanced Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which volrustomig is the first listed.

NCT06129864 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT06129864 about?

NCT06129864 is a clinical study titled "A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy". The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).

What is the current status of trial NCT06129864?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,145 participants. The study started on 2023-12-14. Estimated completion is 2030-09-12.

What conditions does trial NCT06129864 study?

This clinical trial studies the following conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT06129864?

The interventions under investigation include: volrustomig (DRUG).

Who is sponsoring clinical trial NCT06129864?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06129864 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Locally Advanced Head and Neck Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Locally Advanced Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.